Entries by Max

Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC

/in , , /by

A novel double-masked T-cell engager targeting prostate-specific membrane antigen (PSMA), called JANX014, has entered phase 1 testing in patients with metastatic castration-resistant prostate cancer (mCRPC). The first-in-human, open-label, multicenter trial, which dosed its initial participant in mid-April 2026, evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity through ascending intravenous doses administered as monotherapy to […]

Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors

/in , , , /by

PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s […]

CEACAM5 Radiotheranostics: A Targeted Strategy for PSMA-Negative, Neuroendocrine Prostate Cancer

/in , /by

For prostate cancer patients with low expression of PSMA or with neuroendocrine prostate cancer or NEPC (a population growing in size precisely because better treatments are forcing tumors to adapt), a new preclinical study offers a credible precision-targeted strategy: a radiotheranostic pair built on the CEACAM5 surface antigen that produced complete tumor responses in every […]

Phase 1/2 Trial for AZD8359: a CD8-Biased T Cell Engager Targeting STEAP2 in m CRPC

/in , , , /by

Bispecific T cell engagers, while conceptually powerful, have carried a toxicity profile that constrains their clinical utility. AZD8359, a novel trispecific T cell engager now entering its first-in-human clinical trial, represents a thoughtful attempt to resolve that toxicity problem at the molecular engineering level, and its preclinical data are among the most compelling seen in this […]

Newsletter 16/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! The annual AACR 2026 meeting has just started and we already have some very interesting clinical and preclinical studies for you. Stay strong and fight on! ​Picture: Borghetto sul Mincio (near my place), I cross the bridge quite often, […]

UPDATE: Phase 1 Trial of HSK46575, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer

/in , , /by

HSK46575, a novel CYP11A1 inhibitor designed to suppress the entire steroidogenesis pathway, continues to generate interest in advanced prostate cancer, with new early-phase clinical data providing a clearer picture of its activity and tolerability in patients. At the latest data cut-off, 27 patients with advanced prostate cancer had been treated across dose-escalation cohorts ranging from […]

ITRI-148: A Next-Generation AR Degrader Targeting Resistance at Its Core

/in , /by

A new experimental compound, ITRI-148, may represent a meaningful shift in how advanced prostate cancer is treated, particularly in patients who develop resistance to current androgen receptor (AR)-targeted therapies. Resistance to drugs like enzalutamide is frequently driven by AR splice variants such as AR-V7, which lack the ligand-binding domain (LBD) targeted by existing therapies, allowing […]

ProTCE-PSMA Pushes PSMA T-Cell Engagers Toward a Safer Therapeutic Window

/in , /by

A new generation of PSMA-targeted T-cell engagers is emerging with a clear goal: preserve the potency seen in hematologic malignancies while overcoming the safety and efficacy barriers that have limited success in solid tumors. A preclinical candidate, ProTCE-PSMA, presented ahead of IND filing in early 2026, illustrates how rapidly this field is evolving beyond first-generation […]

DLL3-Targeted ADC ZL-1310 Shows Early Promise in Neuroendocrine Carcinomas

/in , , /by

Early-phase data from the ZL-1310-002 trial introduce a potentially important new therapeutic option for patients with advanced neuroendocrine carcinomas (NECs), a group of aggressive malignancies with very limited treatment options after platinum-based chemotherapy. Among these, neuroendocrine prostate cancer (NEPC) represents one of the most clinically challenging subtypes, characterized by rapid progression, resistance to androgen receptor–targeted […]